News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
23.05.2019 07:14:51

Press Release: Novartis highlights company -2-

business models; our performance on environmental, social and governance

measures; general political, economic and trade conditions, including

uncertainties regarding the effects of ongoing instability in various

parts of the world; uncertainties regarding future global exchange

(Anzeige)Passende neue Barrier Reverse Convertibles

rates; uncertainties regarding future demand for our products;

uncertainties regarding potential significant breaches of data security

or data privacy, or disruptions of our information technology systems;

and other risks and factors referred to in Novartis AG's current Form

20-F on file with the US Securities and Exchange Commission. Novartis is

providing the information in this presentation as of this date and does

not undertake any obligation to update any forward-looking statements as

a result of new information, future events or otherwise.

All product names appearing in italics are trademarks owned by or

licensed to Novartis Group companies.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 750 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at


For Novartis multimedia content, please visit


For questions about the site or required registration, please contact


# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Eric Althoff Antonio Ligi

US External Communications Global External Communications

+1 646 438 4335 +41 61 324 1374

eric.althoff@novartis.com antonio.ligi@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 862 778 3275

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2244980/886729.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;


(END) Dow Jones Newswires

May 23, 2019 01:15 ET (05:15 GMT)

Analysen zu Novartis AGmehr Analysen

12.06.19 Novartis Conviction Buy Goldman Sachs Group Inc.
04.06.19 Novartis Underweight JP Morgan Chase & Co.
04.06.19 Novartis Neutral UBS AG
30.05.19 Novartis Underweight Morgan Stanley
29.05.19 Novartis Underweight JP Morgan Chase & Co.

Eintrag hinzufügen

Aktien in diesem Artikel

Novartis AG 91.43 1.95% Novartis AG
Novartis AG (Spons. ADRS) 91.30 1.72% Novartis AG (Spons. ADRS)

Finanzen.net News